News for Atossa Therapeutics, Inc. (ATOS.MX)

In a recent update, Ascendiant Capital has made adjustments to its outlook on Atossa Therapeutics (ATOS). The analyst firm, led by Edward Woo, has maintained it

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Atossa Therapeutics (ATOS) has shared comprehensive findings from the Phase 2 Endocrine Optimization Pilot (EOP) sub-study, part of the I-SPY2 TRIAL. This study

PR NewswireSEATTLE, May 14, 2025 Feasibility endpoint achieved; rapid Ki”‘67 suppression and substantial MRI”‘confirmed tumor shrinkage observed with fav

Key Highlights: Atossa Therapeutics secures U.S. patent for (Z)-endoxifen oral formulations. Average analyst price target suggests a potential upside of

Atossa Therapeutics (ATOS) has successfully secured a new patent from the United States Patent and Trademark Office. This patent is focused on the creation of h

Atossa Therapeutics (ATOS) has announced plans for an innovative Phase 3 trial named SMART 2.0. This study aims to evaluate the effectiveness of oral (Z)-endoxi

Atossa Therapeutics (ATOS) has proposed a Phase 3 study, SMART 2.0, to reduce interval breast cancer in high-risk women. Phase 2 results showed a 20

**media[608912]**

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ( PSTV) (the ”œCompany”), a clinical-stage pharmaceutical company developing targeted r

PR NewswireCAMBRIDGE, Mass., April 10, 2025 CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing int

Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics

SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ( ATOS) (”œAtossa” or the ”œCompany”), a clinical-stage biopharmaceutical company

**media[563205]**

**media[522585]**

**media[507004]**

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ( ATOS) (”œAtossa” or the ”œCompany”), a clinical-stage biopharmaceutical company d

Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Th

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presen